Skip to Navigation Skip to Search Skip to Content
Search All Centers

NICE Approval of Ibrutinib for Chronic Lymphocytic Leukemia (CLL)

View next

Published on February 3, 2017

What does the NICE ibritunib (Imbruvica) approval mean for CLL patients in the UK? Dr. Peter Hillmen of St. James' University Hospital, Leeds (UK) provides an update on the recent approval of the use of ibrutinib by NICE and explains access to patients and the results of the latest clinical trials. 

This program has been supported by AbbVie through an unrestricted grant to the Patient Empowerment Foundation (PEF).

Featuring

Sponsors

Patient Empowerment Network
View next